Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Update: immunological strategies for prostate cancer.

Drake CG, Antonarakis ES.

Curr Urol Rep. 2010 May;11(3):202-7. doi: 10.1007/s11934-010-0106-8. Review.

2.

Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Bilusic M, Heery C, Madan RA.

Vaccine. 2011 Sep 2;29(38):6485-97. doi: 10.1016/j.vaccine.2011.06.088. Epub 2011 Jul 7. Review.

3.

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.

Buonerba C, Ferro M, Di Lorenzo G.

Expert Rev Anticancer Ther. 2011 Jan;11(1):25-8. doi: 10.1586/era.10.180. Review.

PMID:
21166508
4.

Current status of immunological approaches for the treatment of prostate cancer.

Drake CG, Antonarakis ES.

Curr Opin Urol. 2012 May;22(3):197-202. doi: 10.1097/MOU.0b013e3283519ad5. Review.

5.

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

Antonarakis ES, Drake CG.

Curr Opin Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0. Review.

6.

Immunotherapy for the treatment of prostate cancer.

Di Lorenzo G, Buonerba C, Kantoff PW.

Nat Rev Clin Oncol. 2011 May 24;8(9):551-61. doi: 10.1038/nrclinonc.2011.72. Review.

PMID:
21606971
7.

Recent advances in immunotherapy for the treatment of prostate cancer.

Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW.

Expert Opin Biol Ther. 2011 Aug;11(8):997-1009. doi: 10.1517/14712598.2011.575357. Epub 2011 Jun 15. Review.

PMID:
21675925
8.

Update on prostate cancer vaccines.

Drake CG.

Cancer J. 2011 Sep-Oct;17(5):294-9. doi: 10.1097/PPO.0b013e3182325e78. Review.

9.

Development of novel immune interventions for prostate cancer.

Agarwal N, Padmanabh S, Vogelzang NJ.

Clin Genitourin Cancer. 2012 Jun;10(2):84-92. doi: 10.1016/j.clgc.2012.01.012. Epub 2012 Mar 10. Review.

PMID:
22409862
10.

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.

Singh BH, Gulley JL.

Asian J Androl. 2014 May-Jun;16(3):364-71. doi: 10.4103/1008-682X.122585. Review.

11.

Therapeutic prostate cancer vaccines: a review of the latest developments.

Mohebtash M, Madan RA, Gulley JL, Arlen PM.

Curr Opin Investig Drugs. 2008 Dec;9(12):1296-301. Review.

12.

Therapeutic vaccines for prostate cancer.

Cha E, Fong L.

Curr Opin Mol Ther. 2010 Feb;12(1):77-85. Review.

PMID:
20140819
13.

Progress in active specific immunotherapy of prostate cancer.

Tjoa BA, Murphy GP.

Semin Surg Oncol. 2000 Jan-Feb;18(1):80-7. Review.

PMID:
10617899
14.

From bench to bedside: immunotherapy for prostate cancer.

Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ.

Biomed Res Int. 2014;2014:981434. doi: 10.1155/2014/981434. Epub 2014 Sep 4. Review.

15.

Promising novel immunotherapies and combinations for prostate cancer.

Arlen PM, Mohebtash M, Madan RA, Gulley JL.

Future Oncol. 2009 Mar;5(2):187-96. doi: 10.2217/14796694.5.2.187. Review.

16.

Preclinical and clinical development of DNA vaccines for prostate cancer.

Colluru VT, Johnson LE, Olson BM, McNeel DG.

Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Epub 2013 Dec 12. Review.

17.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
18.

Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.

Hwang C, Sanda MG.

Curr Opin Mol Ther. 1999 Aug;1(4):471-9. Review.

PMID:
11713762
19.

Molecular insights into the development of T cell-based immunotherapy for prostate cancer.

Dong B, Minze LJ, Xue W, Chen W.

Expert Rev Clin Immunol. 2014 Nov;10(11):1547-57. doi: 10.1586/1744666X.2014.962515. Epub 2014 Sep 26. Review.

PMID:
25259804
20.

Current immunotherapeutic strategies in prostate cancer.

Grosso JF, Drake CG.

Surg Oncol Clin N Am. 2007 Oct;16(4):861-71, x. Review.

PMID:
18022549

Supplemental Content

Support Center